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ABSTRACT
Background: Artificial intelligence (AI) and machine learning (ML) approaches in combination with
Raman spectroscopy (RS) to obtain accurate medical diagnosis and decision-making is a way forward
for understanding not only the chemical pathway to the progression of disease, but also for tailor-made
personalized medicine. These processes remove unwanted affects in the spectra such as noise, fluor-
escence and normalization, and help in the optimization of spectral data by employing chemometrics.
Methods: In this study, breast cancer tissues have been analyzed by RS in conjunction with principal
component (PCA) and linear discriminate (LDA) analyses. Tissue microarray (TMA) breast biopsies were
investigated using RS and chemometric methods and classified breast biopsies into luminal A, luminal
B, HER2, and triple negative subtypes.
Results: Supervised and unsupervised algorithms were applied on biopsy data to explore intra and
inter data set biochemical changes associated with lipids, collagen, and nucleic acid content. LDA
predicted specificity accuracy of luminal A, luminal B, HER2, and triple negative subtypes were 70%,
100%, 90%, and 96.7%, respectively.
Conclusion: It is envisaged that a combination of RS with AI and ML may create a precise and accurate
real-time methodology for cancer diagnosis and monitoring.
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Incidence of cancer has arisen enormously during the last
decade, estimated to have 18.1 million new cases and 9.6
million deaths in 2018. According to latest global cancer data,
1 in 5 men and 1 in 6 women worldwide develop cancer during
their lifetime, and 1 in 8 men and 1 in 11 women die from the
disease. Worldwide, the total number of people who are alive
within 5 years of a cancer diagnosis, called the 5-year preva-
lence, is estimated to be 43.8 million [1]. Cancers of the lung,
female breast, and colorectum are the top three cancer types in
terms of incidence, and are ranked within the top five in terms
of mortality (first, fifth, and second, respectively). Together,
these three cancer types are responsible for one-third of the
cancer incidence and mortality burden worldwide. Female
breast cancer ranks as the fifth leading cause of death
(627,000 deaths, 6.6%) because the prognosis is relatively favor-
able, at least in more developed countries. In women, incidence
rates for breast cancer far exceed those for other cancers in
both developed and developing countries, followed by color-
ectal cancer in developed countries and cervical cancer in
developing countries [1]. Breast cancer is the most commonly
diagnosed cancer in women (24.2%, i.e. about 1 in 4 of all new
cancer cases diagnosed in women worldwide are breast can-
cer), and the cancer is the most common in 154 of the 185
countries included in GLOBOCAN 2018 [2]. Breast cancer is also
the leading cause of cancer death in women (15.0%). The major
limitations of current breast cancer screening and diagnostic
approaches are false positives, time delays, needle and open
surgical biopsies, pain and anxiety and harms such as physical,
emotional, social, and financial [3].
Raman spectroscopy (RS) has attracted considerable atten-
tion in recent years due to several practical reasons. This
method does not require any dyes or probes to investigate
molecular and chemical changes in biological tissues. Raman
spectra are information-rich and chemical fingerprint can be
used to quantify multiple components of the sample using
same data set [4]. The principle is based on inelastic light
scattering, also known as Raman scattering, depends on the
change in charge distribution that give rise to the molecular
polarizability [5]. Raman scattered light, including stokes and
anti-stokes transmitted through the optical filter is directed to
a diffraction grating to obtain its composite wavelengths.
Position and intensity of each dispersed, composite wave-
length is translated into the Raman spectrum [6]. These char-
acteristic Raman peaks interpret not only information about
biological components of the cell but also their quality, quan-
tity, symmetry, and orientation the compound. Recently, a
combination of Raman microspectroscopy and machine learn-
ing techniques have been used successfully in the identifica-
tion of various cancers such as lung, breast, cervix, stomach,
brain, skin, oral, leukemia, and bladder cancer [7–24]. Initial RS
studies used near-infrared and visible lasers to identify bio-
chemical profiles of human breast biopsies. Lipid and protein
content of breast tissues were found to be markers for benign
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and malignant states [25–28]. Raman was used to detect
different grades of breast cancer by using qualitative and
quantitative chemical information. Micro-spectroscopic
model was built using nine basic components of breast tissue.
Modeling method has exactly mimicked the breast tissue and
these models were used to predict and characterize the dis-
ease status of the breast biopsies. These studies have estab-
lished correlation between biochemical composition and
disease aggressiveness [29].
RS accompanied by enhanced AI and ML have become
powerful tools in prediction of disease more accurately. Our
previous studies have used AI- and ML-based systematic intel-
ligent control-based approaches for identification of normal
cell lines from breast cancer lines, hypoxic region from prolif-
eration region, and even identification of single cell in 3D
scaffold. These approaches have helped in visualization of
multiple components of single cell and tissue biopsies by
means of fuzzy control, genetic algorithm, PCA, LDA, and
cluster analysis [30–32]. In our previous studies, RS and math-
ematical modeling approaches were employed to characterize
and differentiate two breast cancer and one normal breast cell
lines (MDA-MB-436, MCF-7, and MCF-10A). Spectral features
were detectable in high resolution and RS also offered infor-
mation at the cellular level. RS was used to measure the
different cell lines without the use of an external label and
potentially, non-invasively. Spectra of the cell lines have
revealed differences in the concentration of biochemical com-
pounds such as lipids, nucleic acids, and proteins. Raman
peaks were found to differ in intensity and PCA was able to
identify variations that lead to accurate and reliable separation
of the three cell lines. LDA model of three cell lines was
predicted with 100% sensitivity and 91% specificity. The spe-
cificity of this approach is shown to be sensitive enough to
detect cellular components of within cells [30]. Our studies
were extended from cell lines to multicellular spheroids.
Tumor spheroid model was developed, and it mimics the
characteristics of non-vascular in vitro tumor model. A combi-
nation of Raman and AI and ML approaches were used to
identify chemical changes associated with normal proliferat-
ing, hypoxic, and necrotic regions of T-47D human breast
cancer spheroid model. Raman markers such as low amide I
and high tryptophan content were differentiating three
regions of spheroids [31]. RS was also employed to identify
chemical changes in ductal carcinoma in situ and invasive
carcinoma using breast tissue biopsies. Spectral features of
carcinoma biopsies have shown clear shift toward proteins
and backwards to lipids and triacylglycerides. Different grades
of ductal carcinoma in situ (DCIS) have shown spectral varia-
tions in asymmetric and symmetric vibrations of lipids at high-
frequency region and phosphodiester vibrations in fingerprint
region [33]. In our current study, for the first time, a combina-
tion of Raman and AI and ML approaches have been applied
on different breast cancer biopsies of TMA to identify chemical
changes associated with different subtypes of breast cancer.
Characteristic Raman markers were used to differentiate lumi-
nal A, luminal B, HER2 (Human epidermal growth factor recep-
tor 2) positive, and triple negative subtypes of breast cancer.
Furthermore, intra and inter biochemical changes of within
subtypes using different spectral features, was also identified.
2. Materials and methods
2.1. Sample quantity and preparation
TMA approach has gained much attention in pathological
research analysis. High-throughput analysis of many biopsies in a
single slide can be achieved in short time. It increases research
effectiveness with minimal quantities of tissues [34]. TMA slide
with different breast cancer patient biopsies was used for Raman
analysis. TMA slide and ethical approval was provided by Clinical
Trials Research Unit (CTRU), University of Leeds. Clinical trial name
was Azure and trial Data Transfer Agreement (DTA) ID is Azure_07.
TMA slide has provided information about patient trial number, ER
(Estrogen receptor) status, PR (Progesterone receptor) status, HER2
status, histological grade, and tumor pathology. ER and PR status
has described as 0–8, where 0–2 is regarded as negative, some-
times 3 is also considered as negative. HER status has descried as
0–3, where 0 and 1 is negative, and 3 is positive. Score 2 are
equivocal and need to perform an in situ hybridization method
to ascertain true status. Approximately 30% or slightly less of 2+
are amplified and therefore considered as positive. Histological
grade is represented as low grade, moderate, and high grade [35].
Tumor pathology of breast biopsies were ductal No Special Type
(NST), lobular, mixed (ductal/lobular), mucinous, tubular, and
other types. Majority of breast biopsies belong to ductal NST. A
total 132 biopsy samples were present on TMA slide and known
ER, PR and HER2 status biopsies were used for spectral collection.
Thirty spectra were collected from each biopsy and in total 3,960
spectra were collected from patient biopsies. TMA section was
mounted onto a glass slide and firmly fixed. De-waxing was
achieved using xylene treatment for 30 min, 50% alcohol for
5 min, 70% alcohol for 5 min, and 100% alcohol for 5 min. The
aim of xylene treatment is to remove thewax from the sample and
alcohol treatment rehydrates the sample [31].
2.2. Raman spectral measurements
High quality Raman spectra were collected from TMA breast
biopsies using a non-invasive dispersive micro-Raman system
dxr™ (Thermo Nicolet) equipped with a 532 nm laser. Before
collecting spectral data from biopsies, the system was fully cali-
brated using polystyrene as standard. The sensitivity in terms of
signal to noise ratio of the laser was 1000:1. Laser power of 10 mw
was used and it has not damaged to biological materials, and it
has demonstrated in previous communications. A 50× long work-
ing distance objective was used and a spectrograph aperture was
set to 50-micron pinhole. Spectral collection exposure time was
set to 50 swith five exposures. Twenty spectra were collected from
each cell line over the spectral range 400–3200 cm−1. Thermo
Nicolet OMNIC™ software was employed for data acquisition.
2.3. Data processing and analysis
Spectral range was analyzed between 600 and 3400 cm−1. Breast
biopsies were examined using DXR Raman confocal microscope.
A total of 400 spectra were collected for this study and mean
spectrum of each subtype was collected for comparison studies.
AI approach involved in noise filtering, fluorescence removal,
and spectrum normalization. Substrate subtraction and peak
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measurements were accomplished using OMNIC AtlµsTM soft-
ware and TQ Analyst (Thermo Scientific, Madison, WI, USA).
Data analysis was performed using Unscrambler X 10.2 software
(Camo software, Oslo, Norway). Chemometric methods such as
PCA, LDA, and cluster analysis (CA) were applied in data analysis.
The data were first base line corrected and unit vector normal-
ized (UVN). Every PCA was setup with a minimum of 10 ortho-
gonal variables depending on the spectral region used, where
the number of PCs chosen for each setup described >99% of the
variation. PCA was performed on high-wavenumber (3200–
2600 cm−1), amide I (1750–1500 cm−1), amide III (1400–1200 cm-
−1), and nucleic acid (980–610 cm−1) regions. CA was performed
on full spectral range (3200–400 cm−1) using Wards’ method
squared Euclidean distance. Linear discrimination analysis (LDA)
was applied on classification and prediction accuracy. LDAmodel
was setup over full spectral range. Spectral processing for all LDA
models were baseline correction and unit vector normalization.
Five samples from each group were left out at each pass until
total number of 30 spectra of each subtype predicted.
3. Results
Four hundred spectra were collected from luminal A, luminal B,
HER2, and triple negative subtypes and mean spectra of each
subtype was extracted. The major peaks corresponding biological
component assignments across the whole spectral range of each
subtype are as –CH3, –CH2 and –CH=CH– of lipids and proteins,
Amide I, II and III, C-S stretching, C-H bending, O-P-O vibrations,
phenylalanine, tyrosine, C-C stretching, CH2 twisting, CH2 defor-
mations, and C=C stretching of lipids. The other Raman peaks
observed in these subtypes were nucleic acid bases such as
adenine, thymine, uracil, guanine and cytosine (ring breathing
mode), tryptophan (C-C twisting), proline (C-C stretching), glyco-
gen, CH2, CH3 deformations of lipids. Collagen is the prominent
contributor of amide peaks in breast cancer tissues. This is due to
either C=C stretching of proteins, α-helical structure of proteins or
carbonyl stretches of tumor collagen. Raman peaks of four sub-
types have differed in peak intensities and peak shifts.
Furthermore, chemometric approaches were used to classify four
subtypes. These approaches have assisted in accurate and reliable
classification with improved sensitivity and specificity [36].
3.1. Multivariate analysis
AI provides numerous algorithms to analyze Raman spectra
such as hierarchical cluster analysis and linear discriminant
analysis for disease subtype classification, whereas multivari-
ate analysis technique such as PCA used to standard approach
to analyze spectra data. AI approach has been useful in deci-
sion making between normal and cancer biopsies [37,38]. PCA
was performed on luminal A, luminal B, HER2 positive, and
triple negative subtype spectra in order to focus on variability
existing among subtypes. In this process, we extracted loading
plots from each score plot. These describe the amount of
variation for each variable for a given principal component.
Loading plots not only provide variations of data sets but also
provide correlation of loading point and position of the spec-
tra. Examination of loading plots will offer information
regarding origin of variability with in the data set and based
on this information we can explore biochemical components
and its contribution towards variations among subtypes.
3.2. High-wavenumber region
In the first score plot of PCA lipid region, PC2 has pretty much
separated luminal A from triple negatives, whereas, HER2 posi-
tive and luminal B was dispersed. Notably, luminal A were
grouped at positive sides on the PC-2 axis, whereas, triple nega-
tives were on both axes. PC-3 has shown whole distribution
subtype clusters on positive side of axis whereas a subset of
luminal B has distributed on negative side of the axis. The second
score plot has shown huge mixture of subtype spectra along PC-
3 axis rather than clusters. A three-dimensional PCA plot of high-
wavenumber range has shown good cluster formation in HER2
and triple negative subtypes and weak cluster formation in
luminal A and B subtypes (Figure 1).
PCA loading plot analysis of high-wavenumber region has
described biochemical differences among four subtypes.
Firstly, PC-1 loading plot (blue) describes variations in protein
specific symmetric CH3 vibrations of all subtypes. PC-2 loading
plot (red) has pretty much positively separated luminal A and
majority of triple negatives subtype on 2991 and 2848 cm−1
(CH3 symmetric vibration of lipids and proteins) compared to
remaining subtypes. PC-2 has also negatively separated triple
negative, luminal B subtypes and minority of HER2 subtype
with 3060, 2914 cm−1 (CH stretching of proteins), and
2869 cm−1 (CH2 symmetric and asymmetric stretch of lipids,
and CH2 asymmetric stretch of proteins). PC-3 loading plot
(green) has shown that majority of all subtypes and except
minority of luminal B has positively separated with 2918 cm−1
(CH stretching of proteins) and 2881 cm−1 (CH2 symmetric and
asymmetric stretching vibrations) [36].
3.3. Amide I
The first score plot of PCA Amide I region has shown overall
distribution of four subtypes clusters. PC-2 describes a variation
that is considerably different between luminal A and luminal B.
PC-3 has seen almost four subtype cluster distribution both
negative and positive side of the axis. The second score plot
has also shown pretty different to first plot. PC-1 and PC-2 that
are good for separating luminal A from luminal B, PC-3 does not
really separate any subtype except may be triple negative from
the rest and PC-4 certainly separates triple negative from the rest.
Interestingly, PC-2 has pretty much separated luminal B from
luminal A from luminal B. PC-3 does not really separate any
subtype except may be triple negative from rest of the subtypes.
PC-4 certainly separates triple negative from the rest of subtypes.
A 3D PCA plot of amide I range has shown good cluster forma-
tion for luminal A, HER2 positive, and triple negative subtypes
and weak cluster formation in luminal B subtype. A 3D PCA plot
has shown good separation in luminal A, HER2 positive and triple
negative subtypes whereas luminal B is overlapped with luminal
A using the principal components PC-1, PC-3, and PC-4 (Figure 2).
PCA loading plot analysis of amide I region has described
biochemical differences among four subtypes. Firstly, PC-1
loading plot (blue) has sensitive in protein conformation of
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different subtypes. Every PC of this region is sensitive to
protein conformation. Collagen at 1667 cm−1 (either unor-
dered or β sheets) is positively separated triple negative and
majority of HER2 subtypes. PC-3 loading plot (red) has pretty
much sensitive in 1654 cm−1 (α-helical confirmation of col-
lagen), 1614 cm−1 (tyrosine), 1604 cm−1 (phenylalanine and
tyrosine), and 1576 cm−1 (guanine) and 1634 cm−1 (amide I).
PC-4 loading plot (green) has shown that majority of triple
negative, luminal A, and HER2 subtypes are positively sepa-
rated at 1671 (β sheet structures of protein conformation) and
1575 (ring breathing mode of DNA bases), and some of the
luminal Band HER2 and luminal A are negatively separated at
1601 (phenylalanine) and 1547 (proline) [36]. Collagen was
important for separating luminal A and luminal B from rest
of the subtypes but nucleic acids and amino acids were more
important in separating triple negatives from rest of the sub-
types. In a nut shell, PCA of amide I region is sensitive to
protein conformation of different subtypes.
3.4. Amide III
The first score plot of PCA amide III region, PC-2 has pretty
much separated luminal A from triple negative subtype,
whereas, HER2 positive and luminal B are widely distributed.
All four subtypes were randomly distributed along the PC-3
axis both positive and negative side. A 3D PCA plot of Amide
III range has shown better cluster formation in triple negative
subtypes and weak cluster formation in luminal A, luminal B,
and HER2 positive subtypes. A 3D PCA plot has shown a weak
separation in luminal A whereas luminal B, HER2 positive, and
triple negative subtypes are overlapped using the principal
components PC-1, PC-2, and PC-3 (Figure 3).
PCA-loading plot analysis of Amide III region has described
biochemical differences among four subtypes. Firstly, PC-2
loading plot (red) describes a variation that is sensitive to
protein conformation of different subtypes. It has positively
separated majority of luminal B, HER2, and triple negative
subtypes at 1269 and 1244 and negatively at 1336 cm−1 (pur-
ine bases and collagen assignment). PC-3 loading plot (green)
has pretty much sensitive in 1377 cm−1 (lipid assignments),
1339 cm−1 (C-C stretch of phenylalanine), 1279 cm−1 (amide III
of α-helix), and 1277 cm−1 (amide III of α-helix) [36].
3.5. Nucleic acid region
The first and third score plot of PCA nucleic acid region has
shown clear separation between triple negative and luminal A
subtypes, whereas, HER 2 and luminal B were distributed on
both sides of PC-2 axis. Interestingly, each subtype can be
observed as almost subsets of clusters except few spectra of
Figure 1. 2D and 3D PCA plots and loading plots of high wavenumber region for luminal A (red), B (green), HER2 (blue) and triple negative (brown) subtypes based
on first, second and third principal components (PC).
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luminal A and luminal B. The second score plot has shown
indiscriminate separation of four subtypes across the PC-3 axis.
A 3D PCA plot of nucleic acid range has shown weak two-
subset cluster formation in HER2, three-subset cluster forma-
tion in triple negative subtype and weak cluster formation in
luminal A and B subtype. A 3D PCA plot has shown good
separation in luminal A subtype, whereas, luminal B, HER2, and
triple negative subtypes are overlapped using the principal
components PC-1, PC-2, and PC-3 (Figure 4).
PCA-loading plot analysis of nucleic acid region has described
biochemical differences among four subtypes. Firstly, PC-1 load-
ing plot (blue) is sensitive in 938, 921, 877, and 855 cm−1regions.
PC2 loading plot (red) is pretty much sensitive in 939 and
827 cm−1. PC-3 loading plot (green) has shown positive separa-
tion at 960 cm−1 (phosphate vibrations), 903 cm−1 (C-C skeletal
stretching), 829 cm−1 (O-P-O stretching of DNA and RNA),
783 cm−1 (thymine, uracil and cytosine), 758 cm−1 (tryptophan
and ethanolamine of phosphatidylethanolamine), 643 cm−1 (C-C
twisting mode of tyrosine), and 621 cm−1 (disulfide bridges of
cysteine content). It has negatively separated for 920 cm−1 (pro-
line/glucose/lactic acid), 870 cm−1 (proline/hydroxyproline/
valine and polysaccharides), 814 cm−1 (proline/hydroxyproline/
tyrosine/phosphodiester of RNA), and 770 cm−1 (sugar back-
bones or cyclic ring of nucleic acid bases) [36].
3.6. Cluster analysis
Figure 5 has shown the dendrogram of luminal A (L-A), lumi-
nal B (L-B), HER2 (Her 2), and T-Negative (T-N) subtype (four
sets of each subtype) samples over full spectral range (3200–
400 cm−1). Four main clusters were formed. Some of the
luminal B spectra were mixed with triple negative and HER2
subtypes. Each region has formed pretty much good cluster
and distance measurements has suggested that biochemical
snapshot of full spectral region has shown more similarity
between luminal A and subset of luminal B, and HER2 and
triple negative subtype. One subset of luminal B has shown
similarity with triple negative subtype. Distance measurements
have shown luminal A and B chemically more distant from
HER2 and triple negative subtypes.
3.7. Linear discrimination analysis (LDA)
LDA, one of the AI was used in the classification of breast
cancer subtypes A total 120 spectra (30 spectra each subtype)
was selected and processed using baseline correction and
normalization for predictive classification with LDA. LDA mod-
els were setup over the full spectral range 3200–600 cm−1.
Five samples from each group were left out at each pass until
Figure 2. 2D and 3D PCA plots and loading plots of region for luminal A (red), B (green), HER2 (blue) and triple negative (brown) subtypes based on first, third and
fourth principal components (PC).
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a total number of 30 spectra from each group were tested
against the training group. LDA fusion matrix of four subtypes
of TMA breast biopsies were mentioned in Table 1.
Luminal A subtype was predicted with a sensitivity of 70%
where eight spectra were predicted as Luminal B and one
spectrum predicted as HER2 positive subtype. None of the
Luminal A subtype spectra were misclassified in the triple
negative subtype. Luminal B subtype was predicted with sen-
sitivity of 100% where none of the luminal B spectra were
predicted wrongly. HER2 positive subtype was predicted with
sensitivity of 90% with three spectra were misclassified as
luminal B. Triple negative subtype was predicted with sensi-
tivity of 96.67% where only one spectrum was predicted as
luminal B.
4. Discussion
Current screening and diagnosis approaches such as mammo-
graphy, ultra sound and magnetic resonance imaging (MRI)
have their own limitations. Mammogram generally provides
10–14% false negatives whereas MRI approach is expensive
and lack of potential in visualization of both ductal carcinoma
in situ and invasive ductal carcinoma. RS not only provides
real-time biochemical profile of tissues but also understanding
of the disease as it progresses. Breast cancer biopsies that
were analyzed in our study were mainly ductal carcinoma
NST. Multiple genetic mutations and protein dysfunction are
the main cause of breast cancer [39]. It is a well-known fact
that cancer tissues have higher cell proliferation and meta-
bolic activity that result in changes of concentration and
oxidation states of different chemical species. The major bio-
logical activities observed in cancer cells are loss of differentia-
tion, nuclear enlargement, especially increasing in genetic
material [40]. Spectral changes were identified especially at
lipids, amide I and III regions among luminal A, B, HER2, and
triple negatives subtypes. Furthermore, subtypes were also
classified using supervised and unsupervised algorithms.
Significant spectral variations in terms of peak shifts, shapes,
and intensities were observed among four subtypes.
High-wavenumber region of Raman spectra epitomizes
stretching vibrations of lipids and proteins. These vibrations
represent biochemical profile of lipid metabolism and are
helpful in assessing lipid peroxidation in biological systems
[40]. Lipid biosynthesis is correlated with saturated lipid
Figure 3. 2D and 3D PCA plots and loading plots of region for luminal A (red), B (green), HER2 (blue) and triple negative (brown) subtypes based on first, second
and third principal components (PC).
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content in cells. Lipid peroxidation is directly proportional to
lipid degradation and synthesis of lipids is decreased in low
number saturated fatty acids. Deregulated lipid biosynthesis is
a characteristic feature of cancerous tissues. Lipid profiles of
triple negative and luminal A were similar compared to HER2
positive and luminal B. Changes in peak intensities and shifts
are a result of differences in structural conformations and
concentration of lipids in different subtypes of cancerous
biopsies. Lipid synthesis plays a vital role in cancer develop-
ment and progression [41]. Lipid requirements of mammalian
tissues are fulfilled by uptake of fatty acids and lipoproteins
from the blood stream. Fatty acids and cholesterol production
is restricted to a subset of tissues such as lactating breast, liver,
and adipose tissue. Nevertheless, reactivation of lipid synthesis
has been reported in tumorous tissues [42]. Initial studies
demonstrated that cancerous tissues use de novo lipogenesis
to produce lipids, including fatty acids and phospholipids
[43,44]. In recent years, combination of gene expression and
genome scale metabolic studies of breast cancer has revealed
two important concepts of lipid synthesis in cancerous tissues
[45]. Firstly, biosynthesis of fatty acids is a characteristic fea-
ture of early stages of tumor formation because these play
important role in rapid proliferation of cancer cell. Secondly,
advanced stages of cancer have shown antioxidant nature for
detoxification of reactive oxygen species (ROS) [46]. Low
amount of saturated lipids also represents slow growth beha-
vior of cell. Unsaturated fatty acid content is directly propor-
tional to the cancer progress. High-unsaturated fatty acid
content is present in metastatic stages [47]. This Raman
approach has even identified stromal lipid peak intensity dif-
ferences in individual TMA biopsies. These lipid intensity dif-
ferences and structural information were helpful in
understanding these four subtypes of breast cancer as well
classification. The cancerous breast tissue is subjugated by
protein content and high-wavenumber is useful to study pro-
tein vibrations in terms of amino acid nature. Increase in
protein content and its contribution toward carcinogenesis is
evident in breast cancer and nearly 30% cases are having
amplified gene as protein product in HER2 positive subtypes
[48]. The main difficulty in this region is the interpretation of
Raman bands. The major problem is that most of the lipid and
fatty acid bands overlap with protein bands. Overlap is gen-
erally between CH of lipids with CH3, CH2, and CH of amino
acid side chains. Previous Raman spectroscopic studies based
on breast cancer studies have reported that this region
includes not only aliphatic and aromatic amino acids but
also other amino acids such as histidine, threonine, and pro-
line [49].
Protein metabolism plays a key role in cancer biology in
terms of cell differentiation and cell proliferation, hence,
Figure 4. 2D and 3D PCA plots and loading plots of region for luminal A (red), B (green), HER2 (blue) and triple negative (brown) subtypes based on first, second
and third principal components (PC).
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considered as potential Raman markers in disease identifica-
tion. The second and third steps of central dogma, such as,
transcription (DNA to mRNA synthesis) and translation (mRNA
to protein synthesis) signatures were captured in fingerprint
region through molecular vibrations [50]. Aromatic amino
acids such as tryptophan and tyrosine plays crucial role in
various metabolic processes and are required for rapidly pro-
liferating cancer cells. Previous studies have reported that high
amount of tryptophan in cancerous tissues is also evident and
tryptophan peak can be specifically observed in Raman spec-
trum at 1583 cm−1 [51]. Normal breast tissue has shown
characteristic tryptophan between amide I and amide II and
peak intensity is increased as cancer progresses in tissues.
Peak intensity of tryptophan is increased in cancerous tissues.
Tryptophan peak intensity differences and peak shifts were
observed in four subtypes. Luminal B have shown tryptophan
peak at 1583 cm−1, whereas, luminal A, HER2 positive, and
triple negative subtypes have observed in peak shift. Peak
intensity is similar between HER2 and luminal B subtypes
whereas luminal A has shown low intensity and triple negative
is further lowest. Significant tryptophan changes were
observed and luminal B and HER2 have 10-fold increase com-
pared to triple negative and 5-fold increase compared to
luminal A. Protein content changes will be helpful in different
subtypes of breast tissues. Normal breast tissue has shown less
tryptophan content compared to cancerous tissues.
Tryptophan Peak shift was observed in luminal B subtype
and intensity difference identified in luminal A and triple
negative subtypes because they are lower in intensity.
Recent studies have confirmed that tryptophan metabolic
pathway has significant role in cancer progression.
Indoleamine 2,3-dioxygenase (IDO), rate-limiting enzyme of
tryptophan metabolic pathway, expression profile is asso-
ciated with advancement of breast cancer. Raman can be
helpful in identification of tryptophan signatures in different
subtypes of breast cancer.
Proteins peaks, majority of them amide peaks, result from
carbonyl stretching from polypeptide backbones. The informa-
tion provided by Amide I peak is mainly dependent on their
position and shape. Triple negative subtype has shown amide
I peak with high intensity next to Luminal B subtype whereas
Luminal A and HER2 subtypes have shown less amide I peak
intensities. The higher intensity of amide I represent higher
amount of collagen. Ductal carcinoma in situ and fibroade-
noma samples usually shows large number of cells compared
to other lesions of the breast. Increasing cell nucleus size is
one of the important factors in cancer. Pathologists consider
higher nuclear to cytoplasm ratio is the best way to diagnose
the disease. Amide I peak appeared to 1667 cm−1 in triple
negative subtype and it represents β-sheets of collagen pro-
tein. The structural modes of malignant breast tissue proteins
have shown this peak in previous studies [52]. Amide I vibra-
tions of tumor proteins were shifted to HER2 subtype and
then to luminal A and B. Surface Enhanced Raman
Spectroscopy (SERS) studies of saliva have also described this
Figure 5. Dendrogram of Cluster Analysis results for luminal A (L-A), luminal B (LB), HER2 (Her 2) and T-Negative (T-N) subtype (four sets of each subtype) samples.
CA was performed over the full spectral range using Wards method’s Squared Euclidean distance.
Table 1. LDA fusion matrix of Luminal A, B, HER2 positive and triple negative
subtypes.
Actual
Predicted HER2 Luminal A Luminal B Triple Negative
HER2 27 1 0 0
Luminal A 0 21 0 0
Luminal B 3 8 30 1
Triple Negative 0 0 0 29
Total 30 30 30 30
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peak as C=O stretching vibrations, whereas, spectra of brain
tumors have attributed this peak to C=C stretching vibrations
[53]. Lung cancer studies have shown that Raman peak at
1666 cm−1 was only present in cancerous tissue and it is
assigned to collagen. In this study it was suggested that
collagen content plays important role not only in breast can-
cer but also other cancers as well.
Collagen content can be used as quantitative Raman mar-
kers in disease identification, especially in subtype classifica-
tion [54] and our studies also confirmed the importance of
collagen contents both in identification of cancer and classifi-
cation of subtypes. Due to desmoplastic reaction, stroma of
neoplastic breast tissue starts to accumulate dense fibrous
tissue possessing newly formed ECM components, and predo-
minantly, collagen. Previous studies has established that inva-
sion sites of ductal infiltrating carcinoma have shown
accumulation of type I and III collagens whereas protein
extraction studies have revealed that type V collagen increases
by nearly 10% in Ductal Invasive Carcinoma (DIC) compared to
normal breast tissue. In recent years, gene expression studies
have explored tumor-associated collagen structures (TACS)
related to breast cancer progression [55,56]. Optical
approaches such as Multiphoton and second harmonic gen-
eration microscopy show that TACS is important in cancer
progression using mouse tumor explants and microarrays.
TACS 1 is a limited density collagen and usually appears at
small tumor foci. TACS 2 is tangentially oriented collagen
toward the smooth boundary of tumor and TACS 3 is perpen-
dicularly oriented toward irregular invasive tumor boundary.
TACS 3 is described as a consistent and powerful marker in
disease identification, especially in triple negatives [57]. This
marker is going to be considered as an independent prognosis
key irrespective of tumor grade, size, and receptor status. In
recent years, second harmonic generation (SHG) microscopy is
used to quantify collagen amount and evaluated abnormal
collagen fibrils to study malignancy in different stages of
breast cancer. Apart from SHG microscopy, X-ray scattering
approaches have also proved that collagen content and its
structural associated changes differ in different stages of
breast cancer and also predicted invasion directions in terms
of cancer spreading [58,59].
Multivariate approach (PCA) results on whole spectral
range have shown much overlap in luminal A, HER2, and triple
negative subtypes. Luminal B subtype has separated very well
using PC2 and it formed very good cluster, and this might be
due to less intervariation in biopsies. Overlapping of three
subtypes might indicate that biopsies among these groups
possess many similarities in whole spectral range and this
led us to go for a closer look to explore small spectral regions.
Lipids, amide I, amide III, and nucleic acid regions were
explored using PCA. This is the first time; breast cancer biopsy
data was explored using AI and ML approaches based on
subtype classification. AI approach studies have identified
malignant tissues from normal and benign in various cancers
such as lung cancer [54,60], skin cancer [61,62], brain cancer
[18,63], gastro intestinal cancer [64,65], and oral cancer [66].
Nuclear magnetic resonance studies have revealed that
phospholipids and mitochondrial metabolism were affected
in breast cancer cells and phosphocholine content was
increased nearly 20-fold in primary breast cancer cell lines
and nearly 30-fold in metastatic breast cell lines. In addition
to that, genetic alterations increase choline transport and
enhance the synthesis of phosphocholine and betaine and
decline the choline derived ether lipids in breast cancer cells.
Decreased levels of ATP, phosphocreatine, and influx of pyr-
uvate have clearly shown that mitochondrial metabolism was
damaged in breast cancer cells. Genetic alterations increased
choline transport and enhanced the synthesis of phosphocho-
line and betaine and decline the choline derived ether lipids in
breast cancer cells. Initially, Raman studies identified changes
in fatty acid content and β carotene between normal cancer-
ous biopsies. Later studies proved that protein changes in
normal and ductal carcinoma were observed as peak shifts.
Normal breast tissue has shown C-H protein vibration at
1439 cm−1, whereas, ductal carcinoma NST samples have
shown this peak at 1449 cm−1. Here, all four subtypes have
expressed this peak at 1449 cm−1 and it clearly shows that all
of biopsies were in malignant state. This wavenumber shift is
probably indicative of large lipid accumulation in the malig-
nant state compared to normal breast.
The spectral region between 1400 and 800 cm−1 has repre-
sented six different amino acids such as glycine, alanine, pro-
line, tyrosine, valine, and phenylalanine. These amino acids are
basic backbones of primary structure of proteins. The principal
component of breast tissue is collagen and it is mainly com-
posed of glycine, valine, proline, and phenylalanine. It is clear
that the intensity of these amino acids is increased in Triple
negative subtype compared to the other subtypes. Alanine,
glycine, proline, and tyrosine peak intensities were observed
high in triple negative subtypes and low in luminal B subtypes.
The order in which these amino acid peak intensities decrease
is triple negative to luminal A to HER2 positive to luminal B.
Collagen peak intensity variation is observed in amide I and
amide III regions within individual biopsies. The intensity of
collagen among different breast cancer subtype was much
varied; this difference was due to various concentration of
collagen among the investigated subtypes. Our Raman spec-
tral data has shown that invasive triple negative cancer has
the highest intensity of collagen among all other subtypes.
Raman spectra also reported high collagen associated amino
acids in fibroadenoma and invasive lobular carcinomas [29].
Based on this relative higher amount of collagen content in
triple negative subtype compared to other subtypes have
indicated that this is one of the most pathogenic subtype,
Raman could be in useful in identification of new chemical
pathogenic marker in terms of collagen content.
Amide I peak is shifted gradually toward lower wavenum-
ber in HER2 and luminal subtypes. Maiti et al. reported that
amide I peak at 1667 cm−1 has contributed from β sheet
structures. A sharp peak also represents increased hydrogen
bonding in β sheets of proteins [67,68]. Three shoulder peaks
were observed in amide I region namely 1621, 1605, and
1584 cm−1. The first two shoulder peaks attributed from
amino acids and, later from amino acids and nucleic acids.
Raman peak at 1605 cm−1 in triple negatives, 1604 cm−1 at
HER2, and luminal subtypes have attributed to aromatic amino
acids such as phenylalanine and tyrosine. CARS-based color-
ectal tissue studies have suggested that Raman peak at
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1584 cm−1 is attributed to nucleic acids, whereas, RS-based
nasopharyngeal tissue studies attributed to C=C bending
mode of phenylalanine [69,70]. Previous studies have reported
that these peak intensities are decreased in cancerous tissue
compared to normal. HER2 and luminal B subtypes have
shown increased intensities compared to luminal A and triple
negative subtypes.
Earlier breast cancer studies have reported significant and
reproducible peak shifts in amide II region. Raman Spectra of
normal breast tissue have expressed amide II peak at 1439 cm−1,
whereas, invasive ductal carcinoma biopsies at 1449 cm−1. All four
subtypes have expressed this peak at 1449 cm−1 with peak inten-
sity differences. This is due to CH2 deformations of fatty acid and
proteins. Fatty acid composition varies in breast cancerous tissues.
Triglyceride content is reduced nearly more than half in cancerous
tissues compared to normal, whereas, phospholipid content is
increased four folds in cancerous biopsies. Overall reduced lipid
content in cancerous biopsies was reported. Triple negative and
luminal B subtypes have shown increased peak intensities com-
pared to luminal A and HER2 subtypes. Phospholipid metabolic
studies have revealed that membrane lipids, such as, phosphati-
dylethanolamine and phosphatidylcholine plays vital role in breast
cancers. Membrane lipid content might assist breast tumor inva-
sion as well. Low levels phosphatidylethanolamine act as marker
in early prediction of visceral metastasis. A later phase of metas-
tasis was predominated by low levels of phosphatidylcholine [26].
Normal mice mammary gland has not expressed Raman peak at
1339 cm−1 but mammary tumors have expressed, and it is attrib-
uted to hydrated α-helix δ (N-H) and v(C-N) of elastin proteins. It
might also be attributed to purine bases (adenine and guanine) of
nucleic acid content [71]. Raman peak at 1317 cm−1 represents v
(C-H), CH2 of aliphatic amino acids. All four subtypes have shown
amide III peak at 1245 cm−1 and shoulder peak at 1207 cm−1
attributed to hydroxyproline and tyrosine. Amide III region repre-
sents major vibrations such as N-H bending and C-N stretching
andminor vibrations of C=O in-plane bending and C=C stretching
vibrations [72]. Protein conformation in amide III region is more
complex because it relies on side chain of amino acids, where N-H
bending is responsible formanymodes of vibrations in this region.
Polypeptide backbone and amino acid side-chain vibrations sig-
nificantly vary in this region making it difficult to interpret second-
ary structure of proteins [73]. Overall, higher intensity of amide III is
observed in triple negative subtype and higher protein content
with tyrosine and hydroxyproline was observed in HER2 subtype.
Amide III region has shown triple negative and luminal B has
higher protein content than HER2 and luminal A subtype.
A strong phenylalanine peak was observed in all four sub-
types. Luminal B has showed the highest intensity of phenyla-
lanine compared to other subtypes. The region between 1000
and 600 cm−1 has shown significant collagen associated amino
acid content [26]. Proline and tyrosine are observed in higher
quantities in triple negative subtypes compared to luminal and
HER2 subtypes. It is well-known fact that an increase in collagen
content is a key marker in carcinogenesis [29]. In the case of
breast cancer, desmoplastic reaction leads to deposition of col-
lagen known as reactive fibrosis. Collagen deposition is a stro-
mal indicator to invasive carcinoma. Two prominent peaks
observed around 642 and 620 cm−1 representing C-C twisting
of tyrosine and C-S stretching vibrations. Peak intensities for
these two peaks differed in all four subtypes of breast cancer.
In high-wavenumber, amide I, III, and nucleic acid regions, lumi-
nal B spectra have distributed on both positive and negative
sides of PCA plots. Luminal B has shown considerable spectral
scattering in all regions and one small subset has shown simi-
larity with triple negative subtype whereas majority of them
have shown more similarity toward luminal A subtype.
5. Conclusions
A combination of RS, AI, and ML approaches have great
potential in chemical assessment of cancerous tissues. These
approaches used in this study provide a good cross check to
validate spectral data, the popular method used to classify
breast cancer subtypes spectra is PCA, which has shown
excellent agreements with the results of cluster analysis and
LDA. TMA breast biopsies have shown huge chemical hetero-
geneity not only in different subtypes but also within each
individual subtype. Fatty acid, amide I, and III have contributed
many variations among four subtypes of breast biopsies. Rapid
mapping of large number of biopsies of different subtypes will
be helpful to track changes in collagen and lipid profiles in
each subtype and to establish large database based on these
profiles. Finally, these differences observed in the four sub-
types may also be useful in understanding cancer migration
although this needs confirmation of larger panel of biopsies.
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